1,3-substituted 2-amino-indole derivatives and analogues useful in the treatment or prevention of diabetes mellitus, obesity, and inflammatory bowel disease

Abstract

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Q, X 4 , X 5 , X 6 , X 7 , R 1 , R 2 , R 3 and R 8 are as defined in the specification, processes for the preparation of such compounds, pharmaceutical compositions containing them and the use of such compounds in therapy.

1 . A compound of formula (I): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein
 Q represents —O—, —S—, —SO—, —SO 2 —, —SO 2 NR—, —SO 2 (CH 2 ) m — or —SO 2 O—; 
 R represents a hydrogen atom or a C 1 -C 6  alkyl group; 
 m is 1 or 2; 
 X 4  represents N or CR 4 ; 
 X 5  represents N or CR 5 ; 
 X 6  represents N or CR 6 ; 
 X 7  represents N or CR 7 ; 
 
       provided that one or two of X 4 , X 5 , X 6  and X 7  represents a nitrogen atom;
 R 1  and R 2  each independently represent a hydrogen atom or a C 1 -C 6  alkyl, C 3 -C 8  cycloalkyl or C 1 -C 6  alkoxycarbonyl group, each of which may be optionally substituted by at least one halogen atom; 
 R 3  represents a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom independently selected from nitrogen, oxygen and sulphur, wherein the 3- to 10-membered ring system is optionally substituted by at least one substituent independently selected from halogen, hydroxyl, cyano, C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, C 1 -C 6  hydroxyalkyl, C 1 -C 6  alkoxy, C 1 -C 6  haloalkoxy, C 3 -C 6  cycloalkylC 1 -C 6  alkoxy, C 1 -C 6  alkoxyC 1 -C 6  alkyl, C 1 -C 6  alkylC(O)NR 14 —, phenyl, (halo)phenylcarbonyl, phenoxy, benzyl, benzyloxycarbonyl and a saturated or unsaturated 4- to 6-membered heterocyclyl group, which heterocyclyl group is itself optionally substituted by at least one C 1 -C 6  alkyl group, 
 and when Q represents —SO 2 NR—, R 3  may additionally represent a C 1 -C 6  alkyl group optionally substituted by at least one substituent independently selected from halogen, C 1 -C 6  alkoxy, C 3 -C 6  cycloalkyl, phenyl and a saturated or unsaturated 4- to 6-membered heterocyclyl group; 
 R 4 , R 5  and R 6  each independently represent a hydrogen or a halogen atom, or a C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 1 -C 6  alkylthio, C 1 -C 6  haloalkyl, NR 12 R 13 , C 3 -C 8  cycloalkyl or C 5 -C 8  cycloalkenyl group; 
 R 7  represents a hydrogen or a halogen atom, hydroxyl, cyano, NR 9 R 10 , or a C 1 -C 6  alkyl, C 3 -C 8  cycloalkyl, C 2 -C 6  alkenyl, C 5 -C 8  cycloalkenyl, C 1 -C 6  alkoxy, C 3 -C 8  cycloalkyloxy, benzyloxy, 3-to 11-membered saturated heterocyclyl, 3-to 11-membered saturated heterocyclyloxy, C 6 -C 10  aryl or heteroaryl group, each of which may be optionally substituted by at least one substituent independently selected from halogen, cyano, C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 3 -C 8  cycloalkyl, phenyl and a saturated or unsaturated 4- to 6-membered heterocyclyl group wherein each C 1 -C 6  alkyl, C 1 -C 6  alkoxy, C 3 -C 8  cycloalkyl, phenyl or saturated or unsaturated 4- to 6-membered heterocyclyl substituent group may itself be optionally substituted by at least one substituent independently selected from halogen, C 1 -C 3  alkyl, C 1 -C 3  alkoxy and C 3 -C 6  cycloalkyl; 
 either R 8  represents a saturated 3- to 8-membered ring system which may comprise at least one ring heteroatom independently selected from nitrogen, oxygen and sulphur, wherein the 3- to 8-membered ring system is optionally substituted by at least one substituent independently selected from halogen, hydroxyl and C 1 -C 6  alkyl, or R 8  represents a C 1 -C 6  alkyl group optionally substituted by at least one substituent independently selected from phenyl and C 3 -C 6  cycloalkyl, the cycloalkyl group itself being optionally substituted by at least one C 1 -C 6  alkyl group; 
 R 9  and R 10  each independently represent a hydrogen atom, or a C 1 -C 6  alkyl or —(CH2) p —R 11  group, each of which may be optionally substituted by at least one substituent independently selected from halogen, C 1 -C 3  alkyl and C 1 -C 3  alkoxy; 
 p is 0 or 1; 
 R 11  represents C 3 -C 6  cycloalkyl, phenyl or a saturated or unsaturated 5- to 6-membered heterocyclyl group; and 
 R 12 , R 13  and R 14  each independently represent a hydrogen atom or a C 1 -C 6  alkyl group. 
 
     
     
         2 . A compound according to  claim 1 , wherein X 4  and X 7  are N, X 5  is CR 5  and X 6  is CR 6 . 
     
     
         3 . A compound according to  claim 1 , wherein X 4  and X 6  are both N, X 5  is CR 5  and X 7  is CR 7 . 
     
     
         4 . A compound according to  claim 1 , wherein Q represents —SO 2 —. 
     
     
         5 . A compound according to  claim 1 , wherein R 1  and R 2  are both hydrogen. 
     
     
         6 . A compound according to  claim 1 , wherein R 3  represents a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom independently selected from nitrogen, oxygen and sulphur, optionally substituted as defined in  claim 1 , wherein the ring system is selected from phenyl, thienyl, cyclopropyl, cyclohexyl, pyridinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azetidinyl, 1,4-oxazepanyl, azepanyl, thiomorpholinyl, 1,2,3,4-tetrahydroisoquinolinyl, 2,3-dihydroisoindolyl, azabicyclo[3.2.1]octanyl and 2,3-dihydro-1,4-benzodioxinyl. 
     
     
         7 . A compound according to  claim 1 , wherein R 3  represents phenyl optionally substituted by one or two substituents independently selected from fluorine, chlorine, cyano, methyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy and C 1 -C 3  alkoxy. 
     
     
         8 . A compound according to  claim 1 , wherein R 8  represents a saturated 4- to 7-membered ring system which may comprise at least one ring heteroatom independently selected from nitrogen, oxygen and sulphur, wherein the 4- to 7-membered ring system is optionally substituted by at least one substituent independently selected from halogen, hydroxyl and C 1 -C 2  alkyl, or R 8  represents a C 1 -C 2  alkyl group optionally substituted by at least one substituent independently selected from phenyl and C 3 -C 6  cycloalkyl, the cycloalkyl group itself being optionally substituted by at least one C 1 -C 2  alkyl group. 
     
     
         9 . A compound according to  claim 1 , wherein R 8  represents a C 4 -C 6  cycloalkyl group optionally substituted by at least one substituent independently selected from fluorine, hydroxyl and methyl. 
     
     
         10 . A compound according to  claim 1 , selected from the group consisting of:
 7-(benzenesulfonyl)-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cycloheptyl-7-[(4-methylbenzene)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cycloheptyl-7-[(4-methylbenzene)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclopentyl-7-[(4-methylbenzene)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   7-[(4-chlorobenzene)sulfonyl]-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-[(4-fluorobenzene)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-{[4-(propan-2-yloxy)benzene]sulfonyl}-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(thiophene-2-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   3-(benzenesulfonyl)-1-cyclohexyl-1H-pyrrolo[3,2-b]pyridin-2-amine,   1-cyclopentyl-3-[(4-methylbenzene)sulfonyl]-1H-pyrrolo[3,2-b]pyridin-2-amine,   1-cyclohexyl-3-[(4-methylbenzene)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-2-amine,   7-(cyclohexanesulfonyl)-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-(4,4-difluorocyclohexyl)-7-[(4-methoxybenzene)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   1-(4,4-difluorocyclohexyl)-3-[(4-methoxybenzene)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-2-amine,   3-(benzenesulfonyl)-1-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-2-amine,   3-(benzenesulfonyl)-1-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-2-amine,   3-(benzenesulfonyl)-1-(4,4-difluorocyclohexyl)-1H-pyrrolo[2,3-b]pyridin-2-amine,   7-(benzenesulfonyl)-5-cyclohexyl-5H-pyrrolo[3,2-d]pyrimidin-6-amine,   3-(benzenesulfonyl)-1-cyclohexyl-1H-pyrrolo[2,3-c]pyridin-2-amine,   3-(benzenesulfonyl)-1-(4,4-difluorocyclohexyl)-1H-pyrrolo[3,2-b]pyridin-2-amine,   1-(4,4-difluorocyclohexyl)-3-[(4-methoxybenzene)sulfonyl]-1H-pyrrolo[3,2-b]pyridin-2-amine,   3-(benzenesulfonyl)-1-cyclohexyl-1H-pyrrolo[3,2-c]pyridin-2-amine,   methyl N-[7-(benzenesulfonyl)-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazin-6-yl]carbamate,   3-(benzenesulfonyl)-1-(4,4-difluorocyclohexyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-amine,   7-(benzenesulfonyl)-5-cyclohexyl-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-6-amine,   5-(benzenesulfonyl)-3-chloro-7-cyclohexyl-7H-pyrrolo[2,3-c]pyridazin-6-amine,   5-(benzenesulfonyl)-7-cyclohexyl-7H-pyrrolo[2,3-c]pyridazin-6-amine,   7-(benzenesulfonyl)-5-(4,4-difluorocyclohexyl)-4-ethoxy-5H-pyrrolo[3,2-d]pyrimidin-6-amine,   7-(benzenesulfonyl)-4-(benzyloxy)-5-(4,4-difluorocyclohexyl)-5H-pyrrolo[3,2-d]pyrimidin-6-amine,   6-amino-5-(4,4-difluorocyclohexyl)-7-(phenylsulfonyl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol,   7-(benzenesulfonyl)-4-chloro-5-(4,4-difluorocyclohexyl)-5H-pyrrolo[3,2-d]pyrimidin-6-amine,   7-(benzenesulfonyl)-5-(4,4-difluorocyclohexyl)-4-N-methyl-5H-pyrrolo[3,2-d]pyrimidine-4,6-diamine,   7-(benzenesulfonyl)-5-cyclohexyl-4-N,4-N-dimethyl-5H-pyrrolo[3,2-d]pyrimidine-4,6-diamine,   7-(benzenesulfonyl)-5-cyclopentyl-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-6-amine,   3-(benzenesulfonyl)-1-cyclohexyl-7-methoxy-1H-pyrrolo[2,3-c]pyridin-2-amine,   6-amino-7-(benzenesulfonyl)-5-cyclohexyl-5H-pyrrolo[3,2-d]pyrimidine-carbonitrile,   5-cyclohexyl-7-(2-fluorobenzenesulfonyl)-4-methoxy-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-6-amine,   5-cyclohexyl-7-(3-fluorobenzenesulfonyl)-4-methoxy-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-6-amine,   7-(benzenesulfonyl)-4-methoxy-5-(oxan-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-amine,   6-amino-5-cyclohexyl-N-phenyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   6-amino-5-cyclohexyl-N-(pyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   5-cyclobutyl-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-(2-methylcyclohexyl)-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-butyl-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-phenethyl-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   2-(6-amino-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-5-yl)cyclohexanol,   5-(2-cyclopropylethyl)-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-(4,4-difluoro-cyclohexyl)-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-(2-cyclobutylethyl)-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   7-(phenylsulfonyl)-5-(tetrahydro-2H-pyran-3-yl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-(3,3-dimethylbutyl)-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-((1R*,2R*,4S*)-bicyclo[2.2.1]heptan-2-yl)-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-(cyclopentylmethyl)-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-((1-ethyl cyclopropyl)-methyl)-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-((2,2-dimethylcyclopropyl)methyl)-7-(phenylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(piperidin-1-ylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(pyrrolidin-1-ylsulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   6-amino-5-cyclohexyl-N-propyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   6-amino-5-cyclohexyl-N-methyl-N-propyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   5-cyclohexyl-7-(morpholinosulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-((4-methylpiperidin-1-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-((4-methylpiperazin-1-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-((3-methoxyazetidin-1-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-((4-ethoxypiperidin-1-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-((4,4-dimethylpiperidin-1-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-((3-methylpyrrolidin-1-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-((2-methylpyrrolidin-1-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-((4,4-difluoropiperidin-1-yl)sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   6-amino-N-benzyl-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   6-amino-N,5-dicyclohexyl-N-methyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   5-cyclohexyl-7-(1,4-oxazepane-4-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(4-methoxypiperidine-1-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   6-amino-N-(cyclobutylmethyl)-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   5-cyclohexyl-7-(3,3-dimethylpyrrolidine-1-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(2,6-dimethylmorpholine-4-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   7-(azepane-1-sulfonyl)-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(thiomorpholine-4-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   N-(1-{6-amino-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonyl}piperidin-4-yl)-N-methylacetamide,   6-amino-5-cyclohexyl-N-(oxetan-3-ylmethyl)-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   7-(4-benzylpiperidine-1-sulfonyl)-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazin-6-amine,   6-amino-5-cyclohexyl-N-(3,3,3-trifluoropropyl)-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   5-cyclohexyl-7-(4-phenylpiperidine-1-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   6-amino-5-cyclohexyl-N-(2-phenylethyl)-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   5-cyclohexyl-7-(4-phenoxypiperidine-1-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(3-phenylpyrrolidine-1-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-[4-(trifluoromethyl)piperidine-1-sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-[3-(methoxymethyl)pyrrolidine-1-sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   6-amino-5-cyclohexyl-N-(cyclopropylmethyl)-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   6-amino-5-cyclohexyl-N-(2-methoxyethyl)-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   5-cyclohexyl-7-(3-methoxypyrrolidine-1-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(3,3-dimethylpiperidine-1-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   1-{6-amino-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonyl}piperidin-4-ol,   5-cyclohexyl-7-(1,2,3,4-tetrahydroisoquinoline-2-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   6-amino-N-(butan-2-yl)-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   6-amino-5-cyclohexyl-N-(oxolan-2-ylmethyl)-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   5-cyclohexyl-7-(2,3-dihydro-1H-isoindole-2-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-{4-[(4-fluorophenyl)carbonyl]piperazine-1-sulfonyl}-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(3-phenoxyazetidine-1-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-[3-(piperidin-1-yl)azetidine-1-sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-[3-(1H-pyrazol-1-yl)azetidine-1-sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(3-methylpiperidine-1-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   6-amino-5-cyclohexyl-N-[2-(1,3-thiazol-2-yl)ethyl]-5H-pyrrolo[2,3-b]pyrazine-7-sulfonamide,   8-{6-amino-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonyl}-8-azabicyclo[3.2.1]octan-3-ol,   5-cyclohexyl-7-[4-(2,2,2-trifluoroethyl)-piperazine-1-sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   (1-{6-amino-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonyl}piperidin-4-yl)methanol,   5-cyclohexyl-7-[4-(cyclopropylmethoxy)piperidine-1-sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-[(4-methoxybenzene)-sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(cyclopropanesulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-[(3-fluorobenzene)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-[(2-fluorobenzene)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-[(3-methoxybenzene)-sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-6-amine,   4-{6-amino-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazine-7-sulfonyl}benzonitrile,   7-[(3-chloro-4-methoxybenzene)-sulfonyl]-5-cyclohexyl-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(6-methoxypyridine-3-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-{[4-(trifluoromethoxy)-benzene]sulfonyl}-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)-5H-pyrrolo[2,3-b]pyrazin-6-amine,   5-cyclohexyl-7-{[4-(difluoromethoxy)-benzene]sulfonyl}-5H-pyrrolo[2,3-b]pyrazin-6-amine,   and pharmaceutically acceptable salts of any one thereof.   
     
     
         11 . A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in  claim 1  which comprises
 (a) when NR 1 R 2  represents NH 2 , reacting a compound of formula 
 
       
         
           
           
               
               
           
         
         wherein L 1  represents a leaving group and X 4 , X 5 , X 6 , X 7 , Q and R 3  are as defined in formula (I), with a compound of formula (III), H 2 NR 8 , or a salt thereof wherein R 8  is as defined in formula (I); or 
         (b) when NR 1 R 2  represents NH 2 , reacting a compound of formula 
       
       
         
           
           
               
               
           
         
         wherein L 2  represents a leaving group and X 4 , X 5 , X 6 , X 7  and R 8  are as defined in formula (I), with a compound of formula 
       
       
         
           
           
               
               
           
         
         wherein Q and R 3  are as defined in formula (I); 
         wherein any of compounds (II), (III), (IV) or (V) may optionally be protected; 
         and optionally thereafter carrying out one or more of the following procedures:
 removing any protecting groups 
 converting a compound of formula (I) into another compound of formula (I) 
 forming a pharmaceutically acceptable salt. 
 
       
     
     
         12 . A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in  claim 1 , in association with a pharmaceutically acceptable adjuvant, diluent or carrier, and optionally one or more other therapeutic agents. 
     
     
         13 . (canceled) 
     
     
         14 . A method for treating a condition whose development or symptoms are linked to GPR43 receptor activity, comprising administering a compound of formula (I) as claimed in  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
         15 . A method for treating obesity and/or diabetes, comprising administering a compound of formula (I) as claimed in  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
         16 . A method for treating inflammatory bowel disease, comprising administering a compound of formula (I) as claimed in  claim 1  or a pharmaceutically acceptable salt thereof.